PANEL OF MONOCLONAL ANTIBODIES TO COMMON IDIOTOPES

常见独特位单克隆抗体组

• 批准号: 3489070
• 负责人: LUIGI F BERTOLI
• 金额: $ 5万
• 依托单位: BROOKWOOD BIOMEDICAL
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-09-30 至 1990-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3489070
• 关键词: B lymphocyte; antiidiotype antibody; enzyme linked immunosorbent assay; hybridomas; immunofluorescence technique; immunoregulation; laboratory mouse; lymphocytic leukemia; monoclonal antibody; neoplasm /cancer immunotherapy; radioimmunoassay

Anti-idiotype antibodies (anti-Id) recognize determinants of the immunoglobulin variable region that are individually specific to the immunizing antibody. Fruitful in many scientific fields and promising in clinical trails of combination immunotherapy they are unfortunately one of the most laborious biological reagents to construct. In the course of tracing the origins of B cell malignancies we found that monoclonal anti-Id antibodies react with varying proportions (less than O.1-10%) of normal human B lineage cells. In the present study we will raise anti-Id antibodies and select for antibodies cross-reactive to a high proportion of human plasma cells and monoclonal immunoglobulins. Selected antibodies will be tested for preferential reactivity to Id+ antibodies of a particular isotype and for fine specificity by inhibition assays. The panel of existing and new anti-Id antibodies will be used to screen for expression of cross-reactive Ids by B cell malignancies and human immunoglobulins of clinical and research interest. this approach could spare patients and researchers the long delay in producing tailor-made anti-Id antibodies providing them with reagents for immediate use to monitor or treat B cell disorders. A panel of cross reactive antibodies would lower the cost of anti-Id production and enhance their role in clinical research

抗独特型抗体（抗 Id）识别基因的决定因素 免疫球蛋白可变区是单独特异性的 免疫抗体。在许多科学领域硕果累累，前景广阔 不幸的是，联合免疫疗法的临床试验只是其中之一 构建起来最费力的生物试剂之一。过程中 追踪 B 细胞恶性肿瘤的起源，我们发现单克隆 抗 Id 抗体与不同比例（小于 O.1-10%）的 正常人类 B 谱系细胞。在本研究中，我们将提出抗 ID 抗体并选择高比例交叉反应的抗体 人浆细胞和单克隆免疫球蛋白。已选择 将测试抗体对 Id+ 抗体的优先反应性 特定同种型并通过抑制测定获得良好的特异性。 现有的和新的抗 Id 抗体组将用于筛选 用于 B 细胞恶性肿瘤和人类交叉反应 Id 的表达 具有临床和研究兴趣的免疫球蛋白。这种方法可以 使患者和研究人员在生产定制产品时避免长时间的延误 抗 Id 抗体为他们提供可立即使用的试剂 监测或治疗 B 细胞疾病。一组交叉反应抗体 将降低抗 ID 生产成本并增强其在 临床研究